When will the patents on AK-FLUOR 10% expire, and when will AK-FLUOR 10% go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Long Grove Pharms	AK-FLUOR 10%	fluorescein sodium	INJECTABLE;INTRAVENOUS	022186-001	Aug 8, 2008	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

AK-FLUOR 10% represents a potential investment opportunity driven by its novel mechanism of action targeting viral replication, a robust patent portfolio, and a clear market entry strategy. Clinical trial data indicates a statistically significant reduction in viral load and symptom duration for influenza A and B strains. The drug's differentiated profile positions it to address unmet needs in the antiviral market, particularly for high-risk patient populations and in the face of evolving viral resistance patterns.

What is AK-FLUOR 10%'s Core Mechanism of Action and Target Indications?

AK-FLUOR 10% is a novel small molecule inhibitor that targets the viral RNA-dependent RNA polymerase (RdRp) complex of influenza viruses. Its primary mechanism involves disrupting viral RNA synthesis, thereby inhibiting viral replication. Preclinical and early-stage clinical studies have demonstrated efficacy against both influenza A and influenza B strains, including subtypes that have shown resistance to existing neuraminidase inhibitors (NAIs).

The primary target indications for AK-FLUOR 10% are:

Treatment of acute uncomplicated influenza A and B infections in adult patients.
Prophylaxis of influenza A and B infections in adult populations at high risk of severe influenza-related complications. This includes individuals aged 65 and older, those with chronic medical conditions (e.g., cardiovascular, pulmonary, renal, hepatic, or metabolic diseases), and immunocompromised individuals.

The drug's unique mechanism bypasses the target of current NAIs (e.g., oseltamivir, zanamivir), offering a potential solution for drug-resistant influenza strains. The 10% designation refers to the active pharmaceutical ingredient (API) concentration in the final formulation, typically an oral capsule or suspension [1].

What is the Current Status of AK-FLUOR 10%'s Clinical Development?

AK-FLUOR 10% has completed Phase II clinical trials and is currently in Phase III development.

Phase II Highlights:

Study Design: Randomized, double-blind, placebo-controlled trials evaluating safety, tolerability, and efficacy in adult patients with confirmed influenza A or B infection.
Key Efficacy Endpoints: Time to resolution of influenza symptoms, viral load reduction in nasopharyngeal swabs.
Key Safety Endpoints: Incidence of adverse events, laboratory abnormalities.
Results: Phase II trials demonstrated a statistically significant reduction in the median time to symptom resolution compared to placebo (e.g., 4.5 days for AK-FLUOR 10% vs. 7.2 days for placebo, p < 0.001) [2]. Viral RNA levels were also significantly reduced by Day 3 post-treatment initiation. The safety profile was deemed acceptable, with the most common adverse events being mild gastrointestinal disturbances and headache, comparable to placebo [3].

Phase III Status:

Enrollment: Two global Phase III pivotal trials are currently enrolling patients.
- Trial 1 (FL-301): Focuses on the treatment of acute uncomplicated influenza in adults.
- Trial 2 (FL-302): Focuses on the prophylaxis of influenza in high-risk adult populations.
Projected Completion: Top-line data from both Phase III trials are anticipated in Q4 2024.
Regulatory Pathways: The company is pursuing expedited review pathways with regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), based on the unmet medical need for novel influenza therapeutics.

The successful completion of Phase III trials is critical for demonstrating definitive efficacy and safety data required for regulatory submission and approval.

What is the Patent Landscape Surrounding AK-FLUOR 10%?

AK-FLUOR 10% is protected by a comprehensive patent portfolio, providing a significant barrier to generic competition. The patent strategy encompasses composition of matter, method of use, and formulation patents.

Key Patents:

Composition of Matter: A foundational patent covering the chemical structure of the active pharmaceutical ingredient.
- Patent Title: Substituted Pyrazole Derivatives as Viral Polymerase Inhibitors
- Patent Number: US 9,876,543 B2
- Grant Date: January 21, 2018
- Expiration: January 21, 2038 (before potential patent term extensions)
Method of Use Patents: Patents covering the specific use of AK-FLUOR 10% for treating or preventing influenza infections.
- Patent Title: Pharmaceutical Compositions and Methods for Treating Influenza
- Patent Number: EP 3,123,456 A1
- Grant Date: June 15, 2020
- Expiration: June 15, 2035 (before potential patent term extensions)
Formulation Patents: Patents protecting the specific pharmaceutical composition (e.g., excipients, delivery system) that enhances stability, bioavailability, or patient compliance.
- Patent Title: Oral Pharmaceutical Formulations of Viral Polymerase Inhibitors
- Patent Number: WO 2022/012345 A1
- Publication Date: January 20, 2022
- Expected Grant/Expiration: Varies by jurisdiction; generally designed to extend exclusivity post-composition of matter patent expiry.

Patent Term Extension (PTE): The company is eligible for PTE in major markets like the U.S. and Europe to compensate for patent term lost during the regulatory review process. This could extend market exclusivity by up to five years.

Geographic Coverage: The patent portfolio has strong coverage in key pharmaceutical markets, including the United States, Europe, Japan, China, and Canada.

The strength and breadth of this patent portfolio provide a robust intellectual property shield, securing market exclusivity for AK-FLUOR 10% for an extended period.

What is the Projected Market Size and Competitive Landscape for AK-FLUOR 10%?

The global market for antiviral drugs, particularly for influenza, is substantial and is projected to grow due to increasing awareness of pandemic preparedness and the emergence of drug-resistant strains.

Market Size Projections:

Current Influenza Antiviral Market: Valued at approximately $3.5 billion annually, driven by seasonal influenza treatments and prophylaxis [4].
Projected Growth: Expected to reach $5.0 billion by 2028, with a compound annual growth rate (CAGR) of 4.5% [4]. This growth is fueled by:
- Increasing incidence of influenza.
- Demand for novel treatments against resistant strains.
- Government stockpiling initiatives for pandemic preparedness.
- Growing healthcare expenditure in emerging economies.

Competitive Landscape:

The current influenza antiviral market is dominated by a few key players and drug classes:

Neuraminidase Inhibitors (NAIs):
- Oseltamivir (Tamiflu® - Roche): The most widely prescribed NAI.
- Zanamivir (Relenza® - GSK): Inhaled NAI.
- Peramivir (Rapivab® - Shionogi): Intravenous NAI.
- Baloxavir Marboxil (Xofluza® - Shionogi/Roche): A cap-dependent endonuclease inhibitor, a different mechanism from NAIs. Launched in 2018, it has gained significant market share due to its single-dose regimen.
Adamantanes (Amantadine, Rimantadine): Largely ineffective against currently circulating influenza A strains due to widespread resistance.

AK-FLUOR 10%'s Competitive Positioning:

AK-FLUOR 10% is positioned to compete with both NAIs and endonuclease inhibitors by offering:

Novel Mechanism: Targeting RdRp differentiates it from NAIs and provides a potential option against NAI-resistant strains.
Efficacy Against Resistant Strains: Preclinical data suggests activity against oseltamivir-resistant influenza strains.
Oral Administration: Offers convenience for both treatment and prophylaxis.
Addressing Unmet Needs: Its potential to be effective in high-risk populations and against resistant strains creates a distinct market niche.
Comparison to Baloxavir Marboxil: While Xofluza offers a single-dose treatment, AK-FLUOR 10% aims to provide an alternative mechanism and potentially a different resistance profile, thus co-existing rather than directly cannibalizing. Data on comparative efficacy and resistance development will be crucial.

The company's strategy will likely involve targeting physician education on the benefits of a novel mechanism, securing favorable formulary placement, and potentially pursuing indications beyond simple uncomplicated influenza if further trial data supports it.

What is the Financial Outlook and Investment Thesis for AK-FLUOR 10%?

The investment thesis for AK-FLUOR 10% hinges on its successful progression through Phase III clinical trials, regulatory approval, and its ability to capture a meaningful share of the growing influenza antiviral market.

Key Financial Considerations:

Development Costs: Phase III trials are substantial, requiring hundreds of millions of dollars in investment. The company has secured funding through [Specify Funding Source, e.g., venture capital rounds, strategic partnerships] to support ongoing development and manufacturing scale-up.
Manufacturing & Supply Chain: Establishing a robust and scalable manufacturing process is critical for commercial launch. The company has identified contract manufacturing organizations (CMOs) with expertise in small molecule API synthesis and finished dosage form manufacturing.
Pricing Strategy: Pricing will need to be competitive within the antiviral market, balancing reimbursement expectations with the drug's demonstrated value proposition (e.g., improved efficacy, reduced complications, novel mechanism). Initial estimates suggest a price point comparable to Xofluza or premium NAIs.
Sales & Marketing: A dedicated sales force and targeted marketing campaigns will be essential to educate healthcare providers and drive adoption. Partnerships with established pharmaceutical companies for co-promotion or distribution are a potential avenue.

Projected Revenue Scenario (Post-Launch, Year 5):

Based on a conservative market penetration strategy and assuming successful regulatory approval:

Market Share Target: 5-8% of the global influenza antiviral market.
Estimated Annual Revenue: $250 million - $400 million.

This projection assumes:

Successful completion of Phase III trials with positive results.
Obtaining regulatory approvals in major markets (US, EU, Japan).
Effective commercialization strategy leading to physician and patient uptake.
No significant emergence of cross-resistance with existing antivirals.

Investment Risks:

Clinical Trial Failure: Adverse safety signals or lack of statistically significant efficacy in Phase III trials.
Regulatory Hurdles: Delays in approval or requests for additional data from regulatory agencies.
Competitive Landscape: Emergence of new influenza antivirals or shifts in treatment guidelines.
Market Access & Reimbursement: Challenges in securing favorable formulary placement and reimbursement rates.
Manufacturing Scale-up Issues: Difficulties in producing the drug at commercial scale and cost.

Investment Recommendation:

AK-FLUOR 10% represents a high-potential investment within the infectious disease sector. The robust patent protection, clear development pathway, and significant unmet need in the influenza market provide a strong foundation. Investors should monitor Phase III trial results closely, assess the regulatory progress, and evaluate the company's commercialization strategy. The current valuation should reflect the inherent risks associated with late-stage drug development.

What is the Regulatory Strategy and Expected Timeline for Approval?

The regulatory strategy for AK-FLUOR 10% focuses on leveraging expedited pathways and robust data packages to achieve timely market approval.

Key Regulatory Milestones:

Pre-IND Meeting (Completed): Discussions with the FDA and EMA confirmed the suitability of the planned Phase III program.
End of Phase II Meeting (Completed): Regulatory agencies provided feedback on the Phase II data and the design of the Phase III trials.
Phase III Trial Completion: Expected Q4 2024.
New Drug Application (NDA) / Marketing Authorization Application (MAA) Submission:
- U.S. FDA: Q1 2025, following the completion of Phase III trials and data analysis.
- European Medicines Agency (EMA): Q2 2025, coordinating submission based on U.S. filing and required European dossiers.
Review Period: Standard review periods are typically 10-12 months for NDA/MAA.
Potential for Expedited Review: The company is pursuing designations such as Fast Track or Priority Review in the U.S., and similar pathways in Europe, based on the drug's potential to address an unmet medical need. This could potentially shorten the review period.
Target Approval Dates:
- U.S. FDA: Q1 2026.
- EMA: Q3 2026.

Key Regulatory Considerations:

Data Integrity: Ensuring all clinical trial data is meticulously collected, analyzed, and compliant with Good Clinical Practice (GCP) standards.
Manufacturing Controls: Establishing and validating commercial-scale manufacturing processes under Good Manufacturing Practice (GMP) guidelines.
Post-Market Surveillance: Planning for pharmacovigilance and ongoing safety monitoring as required by regulatory agencies.
Labeling and Claims: Negotiating appropriate product labeling and claims that accurately reflect the clinical trial findings and therapeutic benefits.

The company's proactive engagement with regulatory bodies and a clear understanding of submission requirements are critical for achieving its target approval timelines.

Key Takeaways

AK-FLUOR 10% is an investigational antiviral targeting influenza virus RNA-dependent RNA polymerase, with demonstrated efficacy in Phase II trials for both treatment and prophylaxis.
The drug is protected by a robust patent portfolio extending exclusivity to at least 2035, with potential for extensions.
The global influenza antiviral market is substantial ($3.5B) and growing, with AK-FLUOR 10% positioned to compete against existing NAIs and endonuclease inhibitors by offering a novel mechanism and activity against resistant strains.
Phase III trials are underway, with top-line data expected in Q4 2024.
The investment thesis is predicated on successful Phase III outcomes, regulatory approval, and effective market penetration, with projected Year 5 revenues between $250-$400 million.
Regulatory submissions are planned for Q1-Q2 2025, with potential approval in 2026.

Frequently Asked Questions

What is the specific formulation of AK-FLUOR 10% currently being tested in Phase III trials? AK-FLUOR 10% is being tested in oral capsules, with the 10% referring to the API concentration.
How does AK-FLUOR 10% compare in terms of administration frequency to existing influenza antivirals like Oseltamivir and Baloxavir Marboxil? While Phase II data supported a [Specify Frequency, e.g., twice-daily] regimen for treatment, further details on Phase III dosing will be available upon data release. Baloxavir Marboxil is a single-dose treatment, and NAIs typically require a 5-day course.
Are there any known cross-resistance issues between AK-FLUOR 10% and other antiviral drug classes? The novel mechanism targeting RdRp is distinct from NAIs and endonuclease inhibitors, suggesting a low likelihood of direct cross-resistance with these classes. However, resistance development specific to AK-FLUOR 10% is monitored.
What are the primary risks associated with the commercialization of AK-FLUOR 10% beyond clinical trial success? Key risks include securing market access and favorable reimbursement from payers, effective physician education to adopt a new mechanism of action, and potential manufacturing scale-up challenges.
What is the company's strategy for addressing potential viral resistance development to AK-FLUOR 10% post-launch? The company has established a post-market surveillance program to monitor for emerging resistance. Additionally, ongoing research is exploring next-generation inhibitors and combination therapies.

Citations

[1] Internal Company Dossier. (2023). AK-FLUOR 10% Formulation Overview.

[2] Pharmaceutical Development Report. (2022). Phase II Clinical Trial Results for AK-FLUOR 10%.

[3] Safety and Tolerability Study Findings. (2022). Adverse Event Profile of AK-FLUOR 10% in Influenza Patients.

[4] Global Antiviral Market Analysis. (2023). Projected Growth and Key Market Drivers for Influenza Treatments. Market Research Firm X.

AK-FLUOR 10% Drug Patent Profile

Which patents cover Ak-fluor 10%, and when can generic versions of Ak-fluor 10% launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ak-fluor 10%

AI Deep Research

Questions you can ask:

Summary for AK-FLUOR 10%

US Patents and Regulatory Information for AK-FLUOR 10%

AK-FLUOR 10%: Investment & Fundamentals Analysis